Biofreedom tct10 press final

1,110 views
909 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,110
On SlideShare
0
From Embeds
0
Number of Embeds
4
Actions
Shares
0
Downloads
19
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Biofreedom tct10 press final

  1. 1. BioFreedom: A Prospective Randomized Trial of Polymer-Free Biolimus A9-Eluting Stents and Paclitaxel-Eluting Stents in Patients with Coronary Artery Disease<br />EberhardGrube, MD, FACC, FSCAI<br />on behalf of the BioFreedom Investigators<br />International Heart Center Essen, Germany<br />Hospital A Oswaldo Cruz, Instituto Dante Pazzanese, São Paulo, Brazil<br />Stanford University, School of Medicine, Stanford, CA<br />
  2. 2. BioFreedom™<br />Selectively micro-structured surface holds drug in abluminal surface structures<br />Hypothesis: Polymer-free drug release via porous-eluting stents may reduce late events caused by polymer stent coatings.<br />Potential advantage<br /><ul><li>Avoid long term late adverse effects that might be attributable to the polymer
  3. 3. Improved surface integrity since there is no polymer to be sheared or peeled away from the stent struts
  4. 4. Possible shorter need of dual antiplatelet therapy</li></ul>Proprietary Highly LipophilicLimus drug<br />
  5. 5. BioFreedom <br />standarddose<br />(BFD SD)<br />N=35<br />BioFreedom <br />lowdose<br />(BFD LD)<br />N=36<br />TAXUS® Liberté ®<br />N=36<br />BioFreedom <br />standarddose<br />(BFD SD)<br />N=25<br />BioFreedom <br />lowdose<br />(BFD LD)<br />N=26<br />TAXUS® Liberté ®<br />N=24<br />BioFreedom FIM Design<br />BioFreedom FIM<br />182 patients<br />Second Cohort<br />First Cohort<br />12 Month Clinical FU 99%<br />12 Month Angio FU<br />107 patients<br />4 Month Angio FU<br />75 patients<br />Angio FU 92%<br />Angio FU 92%<br />Enrollment Period<br />Sept 2008 – Jan 2009<br />Enrollment Period<br />Jan 2009 – Jun 2009<br />
  6. 6. BioFreedom FIM Study Design<br />Symptomatic, ischemic heart disease<br />Native coronary artery ≥ 2.25 mm and ≤ 3.0 mm<br />Lesion length ≤ 14 mm<br />Lesion amenable to percutaneous treatment with DES<br />BioFreedom™<br />Standard Dose 15.6 µg/mm<br />BioFreedom™<br />Low Dose 7.8 µg/mm<br />Taxus® Liberté®<br />Clinical Follow-Up<br /> 30 d 4 mo 12 mo 2yr 3yr 4yr 5yr <br />Angio and IVUS Follow-up<br />Primary Endpoint:In-stent Late Lumen Loss (LL) at 12 months (2nd cohort)<br /> Non-Inferiority, margin = 0.24 mm<br />Secondary Endpoints:In-stent Late Lumen Loss (LL) at 4 months (1st cohort)<br />MACE and stent thrombosis rate at 30 days, 4, 12 months, 2, 3, 4 & 5 yrs<br /> Clinically-driven TLR, TVR and TVF at 4, 12 months, 2, 3, 4 & 5 yrs<br /> In-stent/In-segment binary restenosis at 4 months<br /> In-stent/In-segment Minimum Lumen Diameter (MLD) at 4 months<br />Neointimal hyperplasia volume at 4 months measured by IVUS<br /> Biolimus A9 concentrations pre/post procedure at discharge & 30 days<br />DAPT recommended for a minimum of 6 months<br />
  7. 7. 12 Month Angiographic FUIn-Stent Late Lumen Loss: 2nd CohortPrimary Endpoint<br />Non – inferiority <br />P values<br />P = 0.001<br />P = 0.21<br /> (mm)<br />N = 31 <br />N = 31<br />N = 35<br />All values are presented as median [IQR] .<br />
  8. 8. 12 Month Angiographic FUIn-Stent Late Lumen Loss: 2nd CohortPrimary Endpoint<br />Superiority P values<br />P = 0.11<br />P = 0.55<br /> (mm)<br />N = 31<br />N = 31 <br />N = 35 <br />All values are presented as median.<br />
  9. 9. 12 MonthMACE (KM Estimates)All Patients (1st + 2nd Cohorts) <br />*Time to first event<br />**In-hospital MI <br />All p values are non significant.<br />Tests were performed for BFD SD vs. Taxus and BFD LD vs. Taxus.<br />
  10. 10. Possible, probable or definite stent thrombosis as per ARC Definition.<br />All P values are non significant.<br />Tests were performed for BFD SD vs. Taxus and BFD LD vs. Taxus. <br />12 Month Stent ThrombosisAll Patients (1st + 2nd Cohorts) <br />
  11. 11. Summary & Conclusions - 1<br />Primary endpoint (In-Stent LL at 12 months) met: BioFreedom SD non-inferior to Taxus.<br /><ul><li>In-Stent LL for BioFreedom SD (0.17 mm) demonstrated a trend towards superiority at 12 months compared to Taxus (0.35 mm).</li></ul>Both BioFreedom SD and BioFreedom LD demonstrated sustained safety up to 12 months, including absence of stent thrombosis.<br />
  12. 12. Summary & Conclusions - 2<br />BioFreedom: first polymer-free drug coated stent demonstrating comparable efficacy in inhibiting NIH (as assessed by independent QCA analysis) vs. a currently available DES with durable polymer at 12 months in a randomized clinical trial.<br />Larger trial with longer term follow-up warranted to confirm these encouraging results.<br />

×